Please login or register to print this page.

Clinical Articles

Dronedarone approved for use in England and Wales

The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of Multaq® (dronedarone) for the treatment of atrial fibrillation (AF).

The final guidance confirms the earlier decision in the Final Appraisal Determination, published by NICE on 15thJuly, and represents confirmation of that decision, that dronedarone is approved for the treatment of non-permanent AF in people with a cardio-vascular risk factors whose condition is not controlled by standard rate controlling therapies, such as beta blockers.  For these patients, Multaq® is recommended as a therapeutic option.

Dr Derick Todd, Consultant Electrophysiologist at The Liverpool Heart and Chest Hospital, says: “The treatment of AF is about making patients feel better and protecting them from the negative health outcomes associated with AF.  I am excited that dronedarone (Multaq®) is now available, which is a valuable additional choice for the treatment of AF.  For the first time I will feel that a drug I use to treat AF will also reduce the morbidity associated with AF such as hospitalisation, stroke and cardiovascular mortality.”

Indicated in adult clinically stable patients with a history of, or current non permanent atrial fibrillation (AF) to prevent recurrence of AF or lower ventricular rate  dronedarone is the first heart rhythm drug shown in clinical studies not only to maintain normal heart rhythm and reduce ventricular rate, but also to help keep patients out of hospital and to reduce the risk of death due to cardiova scular-related causes, compared to placebo, in addition to standard therapy.

Trudie Lobban, Founder and Chief Executive Officer of the Atrial Fibrillation Association said “The availability of a new treatment for AF is very welcome news for patients with this potentially life-limiting condition. AF affects the quality of life of both patients and their families and it has been a long time since we’ve seen new therapies in this area, giving hope to thousands who are struggling with this debilitating condition.”

Published on: September 20, 2010

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.